JEAN FOUCAULD
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease
- Where
- OKEECHOBEE, FL
- NPI
- 1164414900
- Received
- $37,128 in 412 records, 2019 to 2025 ($15,829 general, $21,298 research)
- As principal investigator
- $3,455,459 of research payments to others in 407 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 58 | $2,201 |
| 2024 | General payment | 67 | $4,307 |
| 2024 | Research payment | 2 | $21,298 |
| 2023 | General payment | 69 | $4,118 |
| 2022 | General payment | 50 | $1,781 |
| 2021 | General payment | 79 | $1,464 |
| 2020 | General payment | 35 | $935 |
| 2019 | General payment | 52 | $1,020 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 2 | $21,298 |
| Food and Beverage | 371 | $9,996 |
| Travel and Lodging | 32 | $5,374 |
| Education | 7 | $458 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-17 | E.R. Squibb & Sons, L.L.C. | $4 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2025 | |
| 2025-12-11 | Kestra Medical Technology Services, Inc. | $33 | Food and Beverage | Cash or cash equivalent | Assure WCD Device, Cardiology/Vascular Diseases | 2025 | |
| 2025-12-11 | E.R. Squibb & Sons, L.L.C. | $5 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2025 | |
| 2025-11-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-11-12 | Bayer Healthcare Pharmaceuticals Inc. | $34 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-31 | Abbott Laboratories | $19 | Food and Beverage | In-kind items and services | AMPLATZER AMULET Device, Structural Heart | 2025 | |
| 2025-10-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-10-16 | E.R. Squibb & Sons, L.L.C. | $3 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2025 | |
| 2025-10-15 | Merck Sharp & Dohme LLC | $26 | Food and Beverage | In-kind items and services | CAPVAXIVE Biological, VACCINE | 2025 | |
| 2025-10-14 | Abbott Laboratories | $142 | Food and Beverage | In-kind items and services | ENSITE Device, Structural Heart | 2025 | |
| 2025-10-02 | PFIZER INC. | $27 | Food and Beverage | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | 2025 | |
| 2025-09-26 | CVRx, Inc. | $7 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2025 | |
| 2025-09-17 | CVRx, Inc. | $15 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2025 | |
| 2025-09-15 | Abbott Laboratories | $24 | Food and Beverage | In-kind items and services | CARDIOMEMS Device, Structural Heart | 2025 | |
| 2025-09-11 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-09-11 | Novartis Pharmaceuticals Corporation | $3 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-09-04 | Merck Sharp & Dohme LLC | $19 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2025 | |
| 2025-08-28 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $20 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2025 | |
| 2025-08-28 | E.R. Squibb & Sons, L.L.C. | $5 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2025 | |
| 2025-08-21 | E.R. Squibb & Sons, L.L.C. | $10 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2025 | |
| 2025-08-13 | Novartis Pharmaceuticals Corporation | $5 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-08-07 | Abbott Laboratories | $24 | Food and Beverage | In-kind items and services | AVEIR Device, Structural Heart | 2025 | |
| 2025-07-23 | Bayer Healthcare Pharmaceuticals Inc. | $33 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-07-23 | E.R. Squibb & Sons, L.L.C. | $3 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2025 | |
| 2025-07-17 | Boston Scientific Corporation | $28 | Food and Beverage | In-kind items and services | AMS 700 Device, AMS 700_URO | 2025 | |
| 2025-07-16 | Cleerly, Inc. | $15 | Food and Beverage | Cash or cash equivalent | Cleerly Ischemia Device, Cardiology/Vascular Diseases | 2025 | |
| 2025-07-10 | Merck Sharp & Dohme LLC | $21 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2025 | |
| 2025-07-03 | CVRx, Inc. | $15 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2025 | |
| 2025-06-26 | Cleerly, Inc. | $20 | Food and Beverage | Cash or cash equivalent | Cleerly Ischemia Device, Cardiology/Vascular Diseases | 2025 | |
| 2025-06-21 | Novartis Pharmaceuticals Corporation | $244 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-06-21 | Novartis Pharmaceuticals Corporation | $215 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-21 | Novartis Pharmaceuticals Corporation | $214 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-06-21 | Novartis Pharmaceuticals Corporation | $34 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-06-20 | Novartis Pharmaceuticals Corporation | $133 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-18 | CVRx, Inc. | $16 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2025 | |
| 2025-06-18 | Novartis Pharmaceuticals Corporation | $9 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-06-18 | Novartis Pharmaceuticals Corporation | $3 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-06-18 | E.R. Squibb & Sons, L.L.C. | $2 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2025 | |
| 2025-06-12 | Bayer Healthcare Pharmaceuticals Inc. | $24 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-06-11 | E.R. Squibb & Sons, L.L.C. | $16 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2025 | |
| 2025-05-22 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $20 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2025 | |
| 2025-05-20 | Kestra Medical Technology Services, Inc. | $43 | Food and Beverage | Cash or cash equivalent | Assure WCD Device, Cardiology/Vascular Diseases | 2025 | |
| 2025-05-13 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $20 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2025 | |
| 2025-05-02 | CVRx, Inc. | $17 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2025 | |
| 2025-04-30 | E.R. Squibb & Sons, L.L.C. | $15 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2025 | |
| 2025-04-29 | Kestra Medical Technology Services, Inc. | $46 | Food and Beverage | Cash or cash equivalent | Assure WCD Device, Cardiology/Vascular Diseases | 2025 | |
| 2025-04-16 | Esperion Therapeutics, Inc. | $16 | Food and Beverage | In-kind items and services | NEXLETOL Drug, ANTILIPEMIC AGENTS | 2025 | |
| 2025-04-11 | CVRx, Inc. | $5 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2025 | |
| 2025-04-03 | E.R. Squibb & Sons, L.L.C. | $126 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2025 | |
| 2025-04-02 | Bayer Healthcare Pharmaceuticals Inc. | $24 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-03-12 | Cardiac Dimensions, Inc. | $131 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-05 | Bayer Healthcare Pharmaceuticals Inc. | $23 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-03-05 | E.R. Squibb & Sons, L.L.C. | $18 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2025 | |
| 2025-02-20 | CVRx, Inc. | $20 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2025 | |
| 2025-02-19 | Amgen Inc. | $19 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-02-13 | Novo Nordisk Inc | $22 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-02-05 | CVRx, Inc. | $16 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2025 | |
| 2025-02-03 | Kestra Medical Technology Services, Inc. | $79 | Food and Beverage | Cash or cash equivalent | Assure WCD Device, Cardiology/Vascular Diseases | 2025 | |
| 2024-12-27 | CVRx, Inc. | $7 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2024 | |
| 2024-12-03 | Bayer Healthcare Pharmaceuticals Inc. | $20 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2024-11-26 | CVRx, Inc. | $13 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2024 | |
| 2024-11-14 | CVRx, Inc. | $8 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2024 | |
| 2024-11-12 | HEARTFLOW, INC. | $28 | Food and Beverage | Cash or cash equivalent | FFRct Device, Coronary | 2024 | |
| 2024-11-12 | Amgen Inc. | $5 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2024 | |
| 2024-10-23 | HEARTFLOW, INC. | $29 | Food and Beverage | Cash or cash equivalent | FFRct Device, Coronary | 2024 | |
| 2024-10-21 | Medtronic, Inc. | $133 | Food and Beverage | In-kind items and services | AZURE XT DR MRI SURESCAN Device, Pacemakers | 2024 | |
| 2024-10-16 | CVRx, Inc. | $13 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2024 | |
| 2024-10-15 | Amgen Inc. | $6 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2024 | |
| 2024-09-26 | Eli Lilly and Company | $184 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-09-24 | Eli Lilly and Company | $19,410 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION | 2024 | |
| 2024-09-19 | Bayer Healthcare Pharmaceuticals Inc. | $20 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2024-09-18 | E.R. Squibb & Sons, L.L.C. | $14 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2024 | |
| 2024-08-27 | Bayer Healthcare Pharmaceuticals Inc. | $21 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2024-08-08 | CVRx, Inc. | $15 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2024 | |
| 2024-08-07 | Inspire Medical Systems, Inc. | $18 | Food and Beverage | In-kind items and services | INSPIRE Device, NEUROLOGY | 2024 | |
| 2024-08-06 | Lexicon Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-07-30 | Amgen Inc. | $18 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2024 | |
| 2024-07-12 | Abbott Laboratories | $102 | Food and Beverage | In-kind items and services | AMPLATZER AMULET Device, Structural Heart | 2024 | |
| 2024-07-09 | Abbott Laboratories | $14 | Food and Beverage | In-kind items and services | AVEIR Device, Cardiac Rhythm Management | 2024 | |
| 2024-07-09 | CVRx, Inc. | $14 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2024 | |
| 2024-07-02 | Janssen Pharmaceuticals, Inc | $15 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2024 | |
| 2024-06-27 | Bayer Healthcare Pharmaceuticals Inc. | $20 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2024-06-20 | Eli Lilly and Company | $1,888 | Research payment | In-kind items and services | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION | 2024 | |
| 2024-06-20 | Becton, Dickinson and Company | $15 | Food and Beverage | In-kind items and services | Venclose Maven Catheter Device, Vascular/Oncology | 2024 | |
| 2024-06-17 | Eli Lilly and Company | $339 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $339 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $320 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $118 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $51 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $51 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $42 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $42 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $32 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $32 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $32 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $15 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $14 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $14 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-16 | Eli Lilly and Company | $359 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-16 | Eli Lilly and Company | $322 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-16 | Eli Lilly and Company | $151 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-16 | Eli Lilly and Company | $123 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-11 | Amgen Inc. | $116 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2024 | |
| 2024-06-04 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2024 | |
| 2024-06-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2024 | |
| 2024-05-30 | Bayer Healthcare Pharmaceuticals Inc. | $18 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2024-05-29 | Amgen Inc. | $8 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2024 | |
| 2024-05-23 | Biosense Webster, Inc. | $126 | Food and Beverage | In-kind items and services | CARTO 3 Device, Cardiology | 2024 | |
| 2024-05-21 | Lexicon Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-05-14 | CVRx, Inc. | $17 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2024 | |
| 2024-05-01 | Lexicon Pharmaceuticals, Inc. | $25 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-04-17 | CVRx, Inc. | $145 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2024 | |
| 2024-04-09 | Bayer Healthcare Pharmaceuticals Inc. | $20 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2024-04-03 | AstraZeneca Pharmaceuticals LP | $62 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-04-03 | Amgen Inc. | $25 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2024 | |
| 2024-04-02 | AGEPHA Pharma FZ LLC | $19 | Food and Beverage | In-kind items and services | LODOCO Drug, Cardiovascular Diseases | 2024 | |
| 2024-03-14 | Abbott Laboratories | $18 | Food and Beverage | In-kind items and services | AMPLATZER AMULET Device, Structural Heart | 2024 | |
| 2024-03-04 | Bayer Healthcare Pharmaceuticals Inc. | $19 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2024-03-01 | Abbott Laboratories | $139 | Food and Beverage | In-kind items and services | AMPLATZER TALISMAN Device, Structural Heart | 2024 | |
| 2024-02-20 | Bayer Healthcare Pharmaceuticals Inc. | $15 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2024-02-13 | Bard Peripheral Vascular, Inc. | $22 | Food and Beverage | In-kind items and services | Venclose Maven Catheter Device, Vascular/Oncology | 2024 | |
| 2024-02-07 | Medtronic, Inc. | $161 | Food and Beverage | In-kind items and services | LINQ II Device, Cardiac Diagnostics and Monitoring | 2024 | |
| 2024-01-24 | Kestra Medical Technology Services, Inc. | $23 | Food and Beverage | Cash or cash equivalent | Assure WCD Device, Cardiology | 2024 | |
| 2024-01-24 | Amgen Inc. | $7 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2024 | |
| 2024-01-16 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $49 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2024 | |
| 2024-01-16 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $18 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2024 | |
| 2024-01-11 | Bayer Healthcare Pharmaceuticals Inc. | $16 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2023-12-20 | E.R. Squibb & Sons, L.L.C. | $10 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2023 | |
| 2023-12-13 | Merck Sharp & Dohme LLC | $16 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2023 | |
| 2023-11-21 | CVRx, Inc. | $15 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2023 | |
| 2023-11-01 | Abbott Laboratories | $14 | Food and Beverage | In-kind items and services | AVEIR Device, Cardiac Rhythm Management | 2023 | |
| 2023-10-24 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $21 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2023 | |
| 2023-10-19 | Merck Sharp & Dohme LLC | $16 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2023 | |
| 2023-10-10 | Bayer Healthcare Pharmaceuticals Inc. | $14 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-10-06 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | 2023 | |
| 2023-10-03 | Novartis Pharmaceuticals Corporation | $19 | Food and Beverage | In-kind items and services | ENTRESTO Drug, Cardiology/Vascular Diseases | 2023 | |
| 2023-09-28 | E.R. Squibb & Sons, L.L.C. | $114 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2023 | |
| 2023-09-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2023 | |
| 2023-09-19 | E.R. Squibb & Sons, L.L.C. | $15 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2023 | |
| 2023-08-29 | CVRx, Inc. | $17 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2023 | |
| 2023-08-18 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | VYNDAMAX Drug, CARDIOVASCULAR | 2023 | |
| 2023-08-15 | Bayer Healthcare Pharmaceuticals Inc. | $16 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-08-09 | Amgen Inc. | $25 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2023 | |
| 2023-08-08 | Merck Sharp & Dohme LLC | $14 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2023 | |
| 2023-08-01 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2023 | |
| 2023-07-28 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $7 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2023 | |
| 2023-07-27 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | 2023 | |
| 2023-07-27 | E.R. Squibb & Sons, L.L.C. | $7 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2023 | |
| 2023-07-11 | Bayer Healthcare Pharmaceuticals Inc. | $15 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-07-05 | Novartis Pharmaceuticals Corporation | $8 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2023 | |
| 2023-06-27 | Merck Sharp & Dohme LLC | $15 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2023 | |
| 2023-06-01 | Bayer Healthcare Pharmaceuticals Inc. | $16 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-06-01 | Merck Sharp & Dohme LLC | $14 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2023 | |
| 2023-05-18 | Janssen Research & Development, LLC | $292 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-05-18 | Janssen Research & Development, LLC | $292 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-05-18 | Janssen Research & Development, LLC | $125 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-05-18 | Janssen Research & Development, LLC | $60 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-05-18 | Janssen Research & Development, LLC | $41 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-05-18 | Janssen Research & Development, LLC | $40 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-05-18 | Janssen Research & Development, LLC | $40 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-05-18 | Janssen Research & Development, LLC | $25 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-05-18 | Janssen Research & Development, LLC | $20 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-05-18 | Janssen Research & Development, LLC | $20 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-05-17 | Janssen Research & Development, LLC | $292 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-05-17 | Janssen Research & Development, LLC | $125 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-05-17 | Janssen Research & Development, LLC | $60 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-05-17 | Janssen Research & Development, LLC | $41 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-05-17 | Janssen Research & Development, LLC | $41 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-05-17 | Janssen Research & Development, LLC | $40 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-05-17 | Janssen Research & Development, LLC | $25 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-05-17 | Janssen Research & Development, LLC | $20 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-05-17 | Janssen Research & Development, LLC | $20 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-05-12 | E.R. Squibb & Sons, L.L.C. | $1 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2023 | |
| 2023-05-09 | AstraZeneca Pharmaceuticals LP | $22 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2023 | |
| 2023-05-04 | E.R. Squibb & Sons, L.L.C. | $9 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2023 | |
| 2023-04-24 | Janssen Research & Development, LLC | $286 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-04-24 | Janssen Research & Development, LLC | $286 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-04-18 | Amgen Inc. | $18 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2023 | |
| 2023-04-18 | Amgen Inc. | $17 | Education | In-kind items and services | 2023 | ||
| 2023-04-04 | Bayer Healthcare Pharmaceuticals Inc. | $16 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-03-27 | Boston Scientific Corporation | $30 | Food and Beverage | In-kind items and services | WATCHMAN Access System Device, WATCHMAN_IC | 2023 | |
| 2023-03-23 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | ENTRESTO Drug, Cardiology/Vascular Diseases | 2023 | |
| 2023-03-21 | HEARTFLOW, INC. | $128 | Food and Beverage | Cash or cash equivalent | FFRct Device, Coronary | 2023 | |
| 2023-03-11 | Novartis Pharmaceuticals Corporation | $223 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2023 | |
| 2023-03-11 | Novartis Pharmaceuticals Corporation | $221 | Travel and Lodging | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2023 | |
| 2023-03-11 | Novartis Pharmaceuticals Corporation | $39 | Travel and Lodging | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | 2023 | |
| 2023-03-11 | Novartis Pharmaceuticals Corporation | $37 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2023 | |
| 2023-03-11 | Novartis Pharmaceuticals Corporation | $32 | Travel and Lodging | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2023 | |
| 2023-03-11 | Novartis Pharmaceuticals Corporation | $14 | Travel and Lodging | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2023 | |
| 2023-03-10 | Novartis Pharmaceuticals Corporation | $390 | Travel and Lodging | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2023 | |
| 2023-03-10 | Novartis Pharmaceuticals Corporation | $124 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2023 | |
| 2023-03-02 | Merck Sharp & Dohme LLC | $17 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2023 | |
| 2023-02-28 | Amgen Inc. | $20 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2023 | |
| 2023-02-14 | Novartis Pharmaceuticals Corporation | $7 | Food and Beverage | In-kind items and services | ENTRESTO Drug, Cardiology/Vascular Diseases | 2023 | |
| 2023-02-10 | Bayer Healthcare Pharmaceuticals Inc. | $15 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-01-03 | Bayer Healthcare Pharmaceuticals Inc. | $16 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2022-11-17 | Bardy Diagnostics, Inc. | $15 | Food and Beverage | In-kind items and services | Carnation Ambulatory Monitor Device, Cardiac Arrhythmia Monitoring | 2022 | |
| 2022-11-12 | Novartis Pharmaceuticals Corporation | $224 | Travel and Lodging | In-kind items and services | 2022 | ||
| 2022-11-12 | Novartis Pharmaceuticals Corporation | $171 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-11-12 | Novartis Pharmaceuticals Corporation | $24 | Travel and Lodging | In-kind items and services | 2022 |
The latest 200 records of 412.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-17 | Novartis Pharmaceuticals Corporation | CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE | $121 | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With T | 2025 |
| 2025-12-12 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $11,628 | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 |
| 2025-12-12 | Boehringer Ingelheim International GmbH | Cardiology Partners Palm Beach Gardens Office | $169 | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o | 2025 |
| 2025-12-12 | Boehringer Ingelheim International GmbH | Cardiology Partners Palm Beach Gardens Office | $217 | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o | 2025 |
| 2025-12-12 | Boehringer Ingelheim International GmbH | Cardiology Partners Palm Beach Gardens Office | $3,087 | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o | 2025 |
| 2025-12-12 | Boehringer Ingelheim International GmbH | Cardiology Partners Palm Beach Gardens Office | $2,243 | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o | 2025 |
| 2025-12-12 | Boehringer Ingelheim International GmbH | Cardiology Partners Palm Beach Gardens Office | $382 | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o | 2025 |
| 2025-12-12 | Boehringer Ingelheim International GmbH | Cardiology Partners Palm Beach Gardens Office | $169 | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o | 2025 |
| 2025-12-12 | Boehringer Ingelheim International GmbH | Cardiology Partners Palm Beach Gardens Office | $217 | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o | 2025 |
| 2025-12-12 | Boehringer Ingelheim International GmbH | Cardiology Partners Palm Beach Gardens Office | $3,087 | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o | 2025 |
| 2025-12-12 | Boehringer Ingelheim International GmbH | Cardiology Partners Palm Beach Gardens Office | $2,243 | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o | 2025 |
| 2025-12-12 | Boehringer Ingelheim International GmbH | Cardiology Partners Palm Beach Gardens Office | $3,583 | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o | 2025 |
| 2025-12-12 | Boehringer Ingelheim International GmbH | Cardiology Partners Palm Beach Gardens Office | $3,583 | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o | 2025 |
| 2025-12-12 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $516 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-11-19 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $12,335 | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 |
| 2025-11-19 | Boehringer Ingelheim International GmbH | Cardiology Partners Palm Beach Gardens Office | $859 | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o | 2025 |
| 2025-11-19 | Boehringer Ingelheim International GmbH | Cardiology Partners Palm Beach Gardens Office | $69 | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o | 2025 |
| 2025-11-11 | Boehringer Ingelheim Pharma GmbH & Co.KG | Cardiology Partners Palm Beach Gardens Office | $1,669 | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o | 2025 |
| 2025-11-11 | Boehringer Ingelheim Pharma GmbH & Co.KG | Cardiology Partners Palm Beach Gardens Office | $1,669 | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o | 2025 |
| 2025-11-07 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $16,515 | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 |
| 2025-11-05 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $6,594 | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 |
| 2025-10-22 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $2,928 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-09-19 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $21,236 | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 |
| 2025-09-19 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $2,136 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-09-03 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $3,064 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-08-25 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $528 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-08-25 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $14,004 | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 |
| 2025-08-22 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $2,963 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-08-12 | Boehringer Ingelheim Pharma GmbH & Co.KG | Cardiology Partners Palm Beach Gardens Office | $6,676 | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o | 2025 |
| 2025-07-28 | Boehringer Ingelheim International GmbH | Cardiology Partners Palm Beach Gardens Office | $34 | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o | 2025 |
| 2025-07-28 | Boehringer Ingelheim International GmbH | Cardiology Partners Palm Beach Gardens Office | $359 | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o | 2025 |
| 2025-07-28 | Boehringer Ingelheim International GmbH | Cardiology Partners Palm Beach Gardens Office | $36 | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o | 2025 |
| 2025-07-23 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $1,728 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-07-23 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $6,084 | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 |
| 2025-07-22 | Amgen Inc. | CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE | $1,274 | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglut | 2025 |
| 2025-07-08 | Novartis Pharmaceuticals Corporation | CARDIOLOGY PARTNERS, LLC | $42,690 | A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and | 2025 |
| 2025-06-25 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $5,909 | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 |
| 2025-06-23 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $7,744 | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 |
| 2025-06-20 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $20,806 | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 |
| 2025-06-20 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $1,501 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-05-21 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $10,005 | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 |
| 2025-05-16 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $1,728 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-04-23 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $2,400 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-04-23 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $16,999 | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 |
| 2025-03-21 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $22,690 | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 |
| 2025-03-17 | Novartis Pharmaceuticals Corporation | CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE | $147,341 | A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and | 2025 |
| 2025-03-17 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $1,200 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-03-14 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $7,885 | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 |
| 2025-02-25 | Eli Lilly and Company | CARDIOLOGY PARTNERS CLINICAL | $1,007 | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU | 2025 |
| 2025-02-24 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $1,200 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-02-19 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $17,755 | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 |
| 2025-02-11 | Novartis Pharmaceuticals Corporation | CARDIOLOGY PARTNERS, LLC | $12,117 | A multi-center, randomized, double-blind placebo-controlled and open-label active-controlled, parallel-group, 24-week pr | 2025 |
| 2025-02-11 | Novartis Pharmaceuticals Corporation | CARDIOLOGY PARTNERS, LLC | $27,324 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2025 |
| 2025-02-10 | Novartis Pharmaceuticals Corporation | CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE | $51,362 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2025 |
| 2025-01-30 | Novartis Pharmaceuticals Corporation | CARDIOLOGY PARTNERS, LLC | $27,350 | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2025 |
| 2025-01-28 | Novartis Pharmaceuticals Corporation | CARDIOLOGY PARTNERS, LLC | $17,670 | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With T | 2025 |
| 2025-01-27 | Eli Lilly and Company | CARDIOLOGY PARTNERS CLINICAL | $10,116 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION | 2025 |
| 2025-01-22 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $1,681 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-01-22 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $23,187 | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 |
| 2025-01-21 | Eli Lilly and Company | CARDIOLOGY PARTNERS CLINICAL | $113,480 | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU | 2025 |
| 2025-01-15 | Novartis Pharmaceuticals Corporation | CARDIOLOGY PARTNERS, LLC | $14,725 | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With T | 2025 |
| 2025-01-13 | Novartis Pharmaceuticals Corporation | CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE | $157,190 | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2025 |
| 2025-01-07 | Eli Lilly and Company | CARDIOLOGY PARTNERS CLINICAL | $169,823 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION | 2025 |
| 2024-12-23 | Bayer Healthcare Pharmaceuticals Inc. | CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE | $331 | BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a | 2024 |
| 2024-12-18 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $8,012 | 70033093AFL3002 | 2024 |
| 2024-12-16 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $46,087 | 70033093AFL3002 | 2024 |
| 2024-12-16 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $1,644 | 70033093ACS3003 | 2024 |
| 2024-11-20 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $30,842 | 70033093AFL3002 | 2024 |
| 2024-11-19 | Bayer Healthcare Pharmaceuticals Inc. | CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE | $2,763 | BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a | 2024 |
| 2024-11-18 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $1,884 | 70033093ACS3003 | 2024 |
| 2024-11-06 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $6,897 | 70033093AFL3002 | 2024 |
| 2024-10-23 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $16,703 | 70033093AFL3002 | 2024 |
| 2024-10-21 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $2,400 | 70033093ACS3003 | 2024 |
| 2024-10-08 | Bayer Healthcare Pharmaceuticals Inc. | CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE | $4,524 | BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a | 2024 |
| 2024-10-02 | Janssen Research & Development, LLC | Crdlgy Partners-Wellington Ofc | $1,104 | 70033093ACS3003 | 2024 |
| 2024-09-25 | Janssen Research & Development, LLC | Crdlgy Partners | $2,987 | 70033093ACS3003 | 2024 |
| 2024-09-25 | Janssen Research & Development, LLC | Crdlgy Partners | $4,345 | 70033093AFL3002 | 2024 |
| 2024-09-20 | Janssen Research & Development, LLC | Crdlgy Partners | $1,200 | 70033093ACS3003 | 2024 |
| 2024-09-18 | Janssen Research & Development, LLC | Crdlgy Partners | $26,670 | 70033093AFL3002 | 2024 |
| 2024-08-27 | Eli Lilly and Company | CARDIOLOGY PARTNERS CLINICAL | $3,427 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION | 2024 |
| 2024-08-26 | Bayer Healthcare Pharmaceuticals Inc. | CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE | $3,075 | BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a | 2024 |
| 2024-08-21 | Janssen Research & Development, LLC | Crdlgy Partners | $2,089 | 70033093ACS3003 | 2024 |
| 2024-08-20 | Eli Lilly and Company | CARDIOLOGY PARTNERS CLINICAL | $49,888 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION | 2024 |
| 2024-08-19 | Janssen Research & Development, LLC | Crdlgy Partners | $20,799 | 70033093AFL3002 | 2024 |
| 2024-07-26 | Janssen Research & Development, LLC | Crdlgy Partners | $16,750 | 70033093AFL3002 | 2024 |
| 2024-07-24 | Janssen Research & Development, LLC | Crdlgy Partners | $1,200 | 70033093ACS3003 | 2024 |
| 2024-06-27 | Bayer Healthcare Pharmaceuticals Inc. | CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE | $993 | BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a | 2024 |
| 2024-06-25 | Janssen Research & Development, LLC | Crdlgy Partners | $5,034 | 70033093AFL3002 | 2024 |
| 2024-06-19 | Janssen Research & Development, LLC | Crdlgy Partners | $75 | 70033093ACS3003 | 2024 |
| 2024-06-17 | Janssen Research & Development, LLC | Crdlgy Partners | $2,329 | 70033093ACS3003 | 2024 |
| 2024-06-14 | Janssen Research & Development, LLC | Crdlgy Partners | $32,922 | 70033093AFL3002 | 2024 |
| 2024-05-28 | Bayer Healthcare Pharmaceuticals Inc. | CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE | $4,423 | BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a | 2024 |
| 2024-05-22 | Janssen Research & Development, LLC | Crdlgy Partners | $2,396 | 70033093AFL3002 | 2024 |
| 2024-05-22 | Janssen Research & Development, LLC | Crdlgy Partners | $1,261 | 70033093ACS3003 | 2024 |
| 2024-05-02 | Novartis Pharmaceuticals Corporation | CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE | $33,791 | A multi-center, randomized, double-blind placebo-controlled and open-label active-controlled, parallel-group, 24-week pr | 2024 |
| 2024-04-26 | Janssen Research & Development, LLC | Crdlgy Partners | $3,957 | 70033093AFL3002 | 2024 |
| 2024-04-26 | Janssen Research & Development, LLC | Crdlgy Partners | $3,899 | 70033093ACS3003 | 2024 |
| 2024-04-23 | Bayer Healthcare Pharmaceuticals Inc. | CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE | $761 | BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a | 2024 |
| 2024-04-11 | Bayer Healthcare Pharmaceuticals Inc. | CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE | $2,968 | BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a | 2024 |
| 2024-03-25 | Janssen Research & Development, LLC | Crdlgy Partners | $18,741 | 70033093AFL3002 | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Okeechobee, FL, county Okeechobee County, FL, state Florida; placed by its city name.
| Measure | Place (city or town) Okeechobee, FL | County Okeechobee County, FL | State Florida |
|---|---|---|---|
| Population B01003 | 5,479 | 40,816 | 22,416,077 |
| Population, 2020 census P1 | 5,254 | 39,644 | 21,538,187 |
| Median age B01002 | 38.4 | 40.8 | 42.6 |
| Under 18 B01001 | 24.1% | 21.4% | 19.5% |
| 65 and over B01001 | 19.2% | 20.0% | 21.3% |
| Households B11001 | 2,053 | 15,113 | 8,752,810 |
| Foreign born B05002 | 10.2% | 13.4% | 21.9% |
| Median household income B19013 | $57,044 | $57,984 | $74,568 |
| Median family income B19113 | $65,259 | $68,838 | $89,891 |
| Per capita income B19301 | $27,942 | $28,796 | $42,609 |
| Poverty rate B17001 | 15.8% | 18.0% | 12.6% |
| Unemployment rate B23025 | 3.1% | 4.4% | 4.8% |
| Civilian labor force B23025 | 2,574 | 16,698 | 11,016,578 |
| Mean commute (minutes) B08013 | 25.6 | 28.4 | 28.0 |
| Bachelor's degree or higher B15003 | 21.1% | 15.8% | 34.1% |
| Housing units B25001 | 2,273 | 18,572 | 10,256,470 |
| Owner-occupied B25003 | 55.1% | 73.9% | 67.6% |
| Renters B25003 | 44.9% | 26.1% | 32.4% |
| Median home value B25077 | $197,700 | $193,000 | $359,000 |
| Median gross rent B25064 | $1,061 | $1,082 | $1,669 |
| White, not Hispanic B03002 | 51.4% | 61.8% | 50.4% |
| Black B03002 | 8.6% | 7.5% | 14.6% |
| Hispanic or Latino B03002 | 34.0% | 26.1% | 27.4% |
| Asian B03002 | 0.9% | 0.7% | 2.9% |
| American Indian and Alaska Native B03002 | 0.1% | 0.3% | 0.1% |
Economy now FRED unemployment 4.4% in Sep 2026 (4.2% a year earlier); per capita personal income $78,345 in 2025, up 38% in five years (+11.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Okeechobee, FL.
Comments